Disease Modifying Trial Designs and Statistical Analysis
*Chunming M. Li, Pfizer 


Disease modifying drugs development is certainly one of the most challenging areas in terms of design, analysis and registration. In many disease areas (Osteoarthritis and Alzheimer’s disease, for example), such a success would mean great market potential. The roundtable will focus on previous experience, FDA perspective and biomarker applications. Please feel free to bring your case study for group discussion.